Vancomycin intermediate-Resistant Staphylococcus aureus (VISA) Isolated from a patient never received Vancomycin treatment.
Int J Infect Dis. 2014 Dec 24. pii: S1201-9712(14)01756-1.
Zhu X1, Liu C2, Gao S1, Lu Y1, Chen Z1, Sun Z3.
1Department of Clinical Laboratory, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
2Department of Clinical Laboratory, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
3Department of Clinical Laboratory, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. Electronic address: email@example.com.
With the abuse of antibiotic, methicillin-resistant Staphylococcus aureus (MRSA) strain became prevalent. Furthermore, Staphylococcus aureus with character of vancomycin intermediate-resistance (VISA) was found globally since the first report in Japan. The main objectives of this study were to report a case of VISA isolated from a Chinese patient never undergoing Vancomycin treatment, and determine its molecular character.
A total of 9 strains were recovered from a patient during therapeutic process. Antimicrobial susceptibility testing was performed to determine their antibiotic susceptibility patterns. To detect VISA strain’s molecular epidemiological features, growth and morphological characters, we sought to multilocus sequence typing, autolysis assay and transmission electric microscope test. Pulsed-field gel electrophoresis (PFGE) was performed to characterize the heterogeneities of all isolates.
One isolate was found to exhibit vancomycin intermediated-resistant with MIC of 8μg/ml. It was ST239-T030-agr-1, had thickener cell wall, displayed slower growth rate and reduced susceptibility to Triton X-100-induced autolysis than other strains. All 9 strains exhibited the same PFGE pattern.
This is the first report of VISA found in the central of China from a patient never received vancomycin treatment.
– – –